Curanex Pharmaceuticals opens at $3.80, IPO at $4

Curanex Pharmaceuticals opens at $3.80, IPO at $4

Curanex Pharmaceuticals (NASDAQ:CURX), a developmental-stage pharmaceutical company specializing in botanical drugs for inflammatory diseases, has successfully completed its initial public offering (IPO). The company priced its IPO at $4.00 per share, raising $15 million in gross proceeds before underwriting costs. Trading began on August 26, 2025, on the Nasdaq Capital Market under the ticker symbol "CURX," with the offering expected to close on August 27, 2025 [1].

The IPO includes a 45-day option for underwriters to purchase an additional 562,500 shares, potentially increasing the total raise. Proceeds from the IPO will be used to fund the development of Curanex's lead product candidate, Phyto-N, for the treatment of ulcerative colitis. The funding will also support FDA-required toxicology and pharmacokinetic studies, preparation and submission of an Investigational New Drug (IND) application, and general working capital needs [1].

Curanex Pharmaceuticals is headquartered in Jericho, New York, and is focused on discovering and developing botanical drugs for inflammatory diseases. Its lead candidate, Phyto-N, is a botanical extract with proven anti-inflammatory properties. The company has validated Phyto-N's effects in animal models of six inflammatory diseases, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout [1].

The $4.00 share price positions Curanex as a speculative small-cap biotech play. Dominari Securities LLC is acting as the lead underwriter, with Pacific Century Securities LLC and Revere Securities LLC as co-underwriters. The Crone Law Group, P.C. is acting as counsel to the Company, while Sichenzia Ross Ference Carmel LLP is acting as lead counsel to the underwriters [1].

The company's shares opened at $3.80 on August 26, 2025, following the IPO. This opening price represents a slight discount from the IPO price of $4.00 per share. Curanex Pharmaceuticals will continue to advance its lead botanical drug candidate, Phyto-N, through FDA-required studies and into Phase I clinical trials [1].

References:
[1] https://www.stocktitan.net/news/CURX/curanex-pharmaceuticals-inc-announces-pricing-of-its-initial-public-5i69s0yk363h.html